Augmenix scores reimbursement code for SpaceOar
Augmenix said today it won a category 1 current procedural terminology reimbursement code from the American Medical Association for periprostatic implantation of biodegradable material, covering its flagship SpaceOAR device.
The SpaceOar is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer, Augmenix said.
The device is delivered through a small needle as a liquid, which then solidifies into a soft gel that expands the space between the prostate and rectum during radiotherapy. The substance then liquefies and is absorbed and cleared from the body in the patient’s urine...
Source: Mass Device - November 9, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Urology Augmenix Inc. Source Type: news
ASTRO: Brachytherapy Enough for Mid-Risk Prostate Cancer (CME/CE)
(MedPage Today) -- Similar outcomes, fewer side effects vs external beam therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 30, 2016 Category: Hematology Source Type: news
Brachytherapy Alone for Intermediate-Risk Prostate Cancer Brachytherapy Alone for Intermediate-Risk Prostate Cancer
Patients with favorable intermediate-risk prostate cancer can be treated with radioactive-seed brachytherapy alone and thus be spared additional late toxicity associated with the usually standard delivery of external-beam radiation first.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Accuray touts 5-year CyberKnife data in prostate cancer trial
Accuray (NSDQ:ARAY) today released 5-year data from a study of its CyberKnife stereotactic body radiotherapy device for treating prostate cancer, touting a 97% rate of freedom from cancer after treatment at 5-years.
Results from the study were presented at the American Society for Therapeutic Radiology and Oncology’s annual meeting in Boston.
The 21-site, 309-patient trial looked to examine whether dose-escalated SBRT can be administered across multiple institutions without grade 3+ toxicities exceeding 10%. The study followed patients for 5 years and reported toxicity, survival and relapse-free survival outcomes.
At 5 ...
Source: Mass Device - September 26, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology Radiosurgery Accuray Inc. Source Type: news
Study Compares Surgery, Radiation, and Active Monitoring to Treat Prostate Cancer
This study will help inform that discussion for men making what is a highly personal, and often difficult choice,” said Brawley.The study involved about 1,600 men in the United Kingdom aged 50 to 69 who were diagnosed with prostate cancer after having an elevated PSA test result. The men were assigned randomly to get surgery to remove their prostate, external-beam radiation, or active monitoring.While the results showed no difference in death from prostate cancer among the groups after 10 years of monitoring, it remains to be seen whether differences will show up after a longer follow-up period. This could be especia...
Source: American Cancer Society :: News and Features - September 16, 2016 Category: Cancer & Oncology Tags: Prostate Cancer Source Type: news
Reflexion adds $6m to bring Series B to $52m
California-based medtech group RefleXion Medical said yesterday it extended its Series B round of financing, bringing in an extra $6 million to bring the total for the round up to $52 million.
RefleXion Medical said it is developing a biology-guided radiotherapy system for cancer treatment, which is designed to use positron emission tomography to locate and identify tumors during treatments.
“RefleXion’s novel combination of PET imaging and external beam radiation therapy represents a significant innovation in localized cancer treatment. We look forward to identifying compelling clinical applications for biol...
Source: Mass Device - July 20, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Oncology RefleXion Medical Source Type: news
IsoRay touts brachytherapy brain cancer trial
IsoRay (NYSE:ISR) today released results from a prospective trial of intraoperative brachytherapy using its Cesium-131 brachytherapy seeds, touting that 95% of treated tumors showed no regrowth at the operative site.
The study examined the use of the IsoRay’s seeds for treating recurrent aggressive meningiomas by applying seeds embedded in collagen tiles directly to brain tissue after tumor removal. IsoRay called the technique the “GammaTile” approach, but clarified that it is not commercially available.
A total of 95% of the treated tumors showed no radiographic evidence of regrowth of the tumor at the ...
Source: Mass Device - June 21, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Neurological Radiosurgery IsoRay Source Type: news
Elekta inks U.S. brachytherapy distro deal with Kobold Medical.
Elekta (STO:EKTA B) said yesterday it inked a distribution deal with Kobold Medical to distribute its brachytherapy applicators within the U.S.
Through the deal, Elekta will market and distribute 4 kobold applicators, as well as its prostate template, the company said.
“We are pleased to offer our brachytherapy users in the United States these high quality products from Kobold. Adding these solutions to our brachytherapy portfolio will help us better serve the needs of clinical providers,” Elekta North America exec veep Bill Yaeger said in a press release.
Included in the distribution deal is Kobold Medical...
Source: Mass Device - June 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Distribution Radiosurgery Elekta AB Kobold Medical Source Type: news
Duke cancer care in Wake County
Treatment Terms
Cancer
Anal cancer
Bile duct cancer
Bladder cancer
Breast cancer
Colon cancer
Esophageal cancer
Gallbladder cancer
Kidney cancer
Liver cancer
Lung cancer
Oral cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Rectal cancer
Skin cancers
Skull base tumor
Spine cancer
Stomach cancer
Testicular cancer
Throat and voice box cancer
Thyroid cancer
Tracheal cancer
Uterine cancer
...
Source: dukehealth.org: Duke Health News - May 20, 2016 Category: Consumer Health News Authors: dg62 Source Type: news
Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer
Objective: To quantify the journeys and CO emissions if women with breast cancer are treated with risk-adapted single-dose targeted intraoperative radiotherapy (TARGIT) rather than several weeks' course of external beam whole breast radiotherapy (EBRT) treatment.
Setting: (1) TARGIT-A randomised clinical trial ( 2 External 0 0 0 ISRCTN34086741 false http://www.controlled-trials.com/ISRCTN34086741 true false%>) which compared TARGIT with traditional EBRT and found similar breast cancer control, particularly when TARGIT was given simultaneously with lumpectomy, (2) 2 additional UK centres offering TARGIT.
Part...
Source: Current Awareness Service for Health (CASH) - May 10, 2016 Category: Consumer Health News Source Type: news
The 'Pinhole' Cancer Treatment You've Probably Never Heard of
Imagine an exquisitely precise cancer therapy procedure done through a small opening in the body that can: Kill tumor cells, shrink tumors, or regrow the healthy part of a cancerous organ. Deliver chemotherapy or radiation directly to the cancer site. Usually be done as an outpatient procedure with fewer side effects than conventional treatments like chemotherapy. Potentially treat many types of cancer, either alone or combined with other therapies. Sounds too good to be true, right? Not necessarily, since this type of therapy, called interventional oncology, is now being performed hundreds of times every day by sp...
Source: Science - The Huffington Post - March 30, 2016 Category: Science Source Type: news
Interruption of radiation therapy risks cancer recurrence
Cancer patients who miss two or more radiation therapy sessions have a worse outcome than fully compliant patients, investigators have found. The study evaluated 1,227 patients scheduled for courses of external beam radiation therapy for cancers of the head and neck, breast, lung, cervix uterus or rectum from 2007 to 2012. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 9, 2016 Category: Science Source Type: news
Diagnosed With Prostate Cancer, Now What: A New Study Shows That Surgery Is the Best Option
With prostate cancer being one of the leading cancers in men, finding the best way to treat it has become increasingly important. A new study points to why surgery might be the best long term treatment option, especially for men with localized prostate cancer. Researchers from Odette Caner Centre, Sunnybrook Research Institute (University of Toronto, Canada) conducted a meta-analysis of 19 studies comparing the success/survival rates of surgery vs. radiation. All in all, this added up to about 120,000 men who received either surgery or radiation as treatment for their localized prostate cancer. What researchers found was...
Source: Healthy Living - The Huffington Post - December 17, 2015 Category: Consumer Health News Source Type: news
What is and What To Expect from External Breast...
Read about external beam breast radiation therapy, including what you can expect during a radiation session, potential side effects, and useful coping strategies during recovery. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - October 31, 2015 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
